ADC Therapeutics SA (ADCT)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.73 on 9 Oct 2026

0 buys6 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$81.36M

Net income

$142.62M

Free cash flow

$141.44M

Operating margin

-149.3%

Net margin

-175.3%

Revenue growth, 1 yr

14.9%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
2 Apr 2026	Redmile Group, LLC 10% owner	Sold at will	$8.64M	17.2%
2 Apr 2026	Redmile Group, LLC 10% owner	Sold at will	$8.29M	19.8%
1 Apr 2026	Redmile Group, LLC 10% owner	Sold at will	$643.04K	1.1%
1 Apr 2026	Redmile Group, LLC 10% owner	Sold at will	$617.40K	1.3%
31 Mar 2026	Redmile Group, LLC 10% owner	Sold at will	$736.25K	1.3%
31 Mar 2026	Redmile Group, LLC 10% owner	Sold at will	$706.90K	1.4%

41out of 100

Profitability 25

Financial strength 42

Growth 63

Insiders 35

Strongest on growth (63), weakest on profitability (25). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$19.64M

6 sales

Planned sales

under a 10b5-1 plan